Corporate Profile
Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. Eikon is led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Eikon’s vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Eikon’s initial focus is oncology, where the company is advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. Eikon’s believes their product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers.